Evidence map›Paper›PMID 36335391›Full record

ArticleAnnals of clinical microbiology and antimicrobials2022

Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations.

Wei Wang, Shanshan Li, Qiping Ge, Haiping Guo, Yuanyuan Shang, Weicong Ren, Yufeng Wang, Zhongtan Xue, Jie Lu, Yu Pang

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Mutations inJAC-antimicrobial resistance · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Wei Wang *Department of Bacteriology and Immunology, Beijing Key Laboratory On Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, 101149, People's Republic of China.
Shanshan Li *Department of Bacteriology and Immunology, Beijing Key Laboratory On Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, 101149, People's Republic of China.
Qiping Ge *Department of Tuberculosis, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, 101149, People's Republic of China.
Haiping GuoDepartment of Bacteriology and Immunology, Beijing Key Laboratory On Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, 101149, People's Republic of China.
Yuanyuan ShangDepartment of Bacteriology and Immunology, Beijing Key Laboratory On Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, 101149, People's Republic of China.
Weicong RenDepartment of Bacteriology and Immunology, Beijing Key Laboratory On Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, 101149, People's Republic of China.
Yufeng WangInnovation Alliance On Tuberculosis Diagnosis and Treatment, Beijing, 101149, People's Republic of China.
Zhongtan XueInnovation Alliance On Tuberculosis Diagnosis and Treatment, Beijing, 101149, People's Republic of China.
Jie LuBeijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, Beijing Pediatric Research Institute, National Center for Children's Health, Beijing Children's Hospital, Capital Medical University, Beijing, 100045, People's Republic of China. lujiebch@163.com.
Yu PangDepartment of Bacteriology and Immunology, Beijing Key Laboratory On Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, 101149, People's Republic of China. pangyupound@163.com.
Beijing Chest Hospital · CNCapital Medical University · CNCenter for Tuberculosis Control of Guangdong Province · CN

Funding

Beijing Hospitals Authority Ascent Plan DFL20191601Beijing Hospitals Authority Clinical Medicine Development of Special Funding ZYLX202122the Capital's Funds for Health Improvement and Research 2020-1-1041
6 · The paper itself

Abstract

BACKGROUND &

objectivesAccurate determination of antimicrobial resistance profiles is of great importance to formulate optimal regimens against multidrug-resistant tuberculosis (MDR-TB). Although para-aminosalicylic acid (PAS) has been widely used clinically, the reliable testing methods for PAS susceptibility were not established. Herein, we aimed to establish critical test concentration for PAS on the Mycobacterial Growth Indicator Tube (MGIT) 960 in our laboratory settings.

methodsA total of 102 clinical isolates were included in this study, including 82 wild-type and 20 resistotype isolates. Minimum inhibitory concentration (MIC) was determined by MGIT 960. Whole-genome sequencing was used to identify the mutation patterns potentially conferring PAS resistance. Sequence alignment and structure modelling were carried out to analyze potential drug-resistant mechanism of folC mutant.

resultsOverall, the Minimum inhibitory concentration (MIC) distribution demonstrated excellent separation between wild-type and resistotype isolates. The wild-type population were all at least 1 dilution below 4 μg/ml, and the resistotype population were no lower than 4 μg/ml, indicating that 4 μg/ml was appropriate critical concentration to separate these two populations. Of 20 mutant isolates, 12 (60.0%) harbored thyA mutations, 2 (10%) had a mutation on upstream of dfrA, and the remaining isolates had folC mutations. Overall, thyA and folC mutations were scattered throughout the whole gene without any one mutation predominating. All mutations within thyA resulted in high-level resistance to PAS (MIC > 32 μg/ml); whereas the MICs of isolates with folC mutations exhibited great diversity, ranged from 4 to > 32 μg/ml, and sequence and structure analysis partially provided the possible reasons for this diversity.

conclusionsWe propose 4 μg/ml as tentative critical concentration for MGIT 960. The major mechanism of PAS resistance is mutations within thyA and folC in MTB isolations. The whole-gene deletion of thyA locus confers high-level resistance to PAS. The diversity of many distinct mutations scattered throughout the full-length folC gene challenges the PCR-based mutation analysis for PAS susceptibility.

Indexed as

Aminosalicylic AcidMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMutationAminosalicylic AcidAntitubercular AgentsCritical ConcentrationDrug Susceptibility TestingMycobacterium tuberculosisPara-Aminosalicylic Acid

Identifiers

PMID36335391
PMCPMC9637297
OpenAlexW4308260077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.